Therapeutic potential of minor cannabinoids in psychiatric disorders: A systematic review
A B S T R A C T
Interest in cannabinoids’ therapeutic potential in mental health is growing, supported by evidence of the involvement of the endocannabinoid system in psychiatric disorders such as anxiety, depression, and addiction.
While the major cannabinoids cannabidiol (CBD) and Δ9-tetrahydrocannabinol (Δ9-THC) have been more extensively researched, approximately 120 minor cannabinoids from the cannabis plant have been identified.
Although some displayed promising pharmacological profiles, research on their application for psychiatric disorders is fragmented. This systematic review evaluates, for the first time, both preclinical and clinical studies exploring minor cannabinoids’ therapeutic potential in psychiatric disorders.
22 preclinical studies and one clinical study were included, investigating various minor cannabinoids in substance use disorders, anxiety disorders, depressive disorders, trauma and stressor-related disorders, psychotic
disorders, neurodevelopmental disorders, and eating disorders.
Despite the heterogeneous results and the moderate to high risk of bias in several articles, certain compounds demonstrate promise for further investigation:
- Δ8-tetrahydrocannabidivarin (Δ8-THCV) exhibited potential for nicotine addiction;
- Δ9-tetrahydrocannabidivarin (Δ9-THCV) for psychotic-like symptoms;
- cannabidiolic acid methyl ester (CBDA-ME) alleviated anxiety and depression-like symptoms, and
- cannabidivarin (CBDV) autism spectrum disorder-like symptoms.
Read the review at: https://www.sciencedirect.com/science/article/pii/S0924977X24007508
Fig. 3. Forest plot of standardized mean difference (SMD) and confidence interval (CI) for the most effective doses of the compounds under study across selected outcomes. Tests are in round brackets. CAPE, Community Assessment of Psychic Experiences; ***Human study.
More analysis found on LinkedIn:
“Minor Cannabinoids in Psychiatry: New Avenues, New Challenges
Cannabinoids like CBDV, CBDA, CBG and even Δ8-THC are emerging as promising tools for tackling mental health conditions like anxiety, depression and addiction. A recent publication did a scientific review of existing literature about the minor cannabinoids and here’s a snapshot of what it showed:
Δ8-THC: Shows potential for addiction management, particularly in opioid withdrawal. However, its chemical conversion from CBD raises safety concerns due to residual by-products. Stricter regulation and quality checks are critical to benefiting from this cannabinoid while mitigating the risks associated with it’s production
CBDV: Promising for autism, improving sociability and reducing repetitive behaviors in preclinical models, but human studies lacking
CBDA: Offers potential for anxiety and depression with (potentially) effectiveness at lower doses than CBD. However, its instability (think spontaneous decarboxylation) and delivery methods need addressing before widespread use…though, a cannabis tea with a touch of milk sure seems pretty attainable to me
CBG: Despite being on the top of my personal list, there have been mixed results so far, with limited evidence supporting its use for anxiety and stress compared to CBDA and CBD. More exploration is needed to unlock its potential, but i am hopeful for it’s utility in ADHD
This forest plot above evaluates the existing research on minor cannabinoids across numerous psychiatric and neurodevelopmental disorders. Each row represents a study, showing the dose, sample size, and effect size. Positive values (those to the right on the vertical line) indicate a favorable effect, while negative (to the left of the vertical line) or CI-crossing-zero (crossing the vertical line) values suggest no significant benefit.
The plot highlights promising outcomes for cannabinoids like CBDV in neurodevelopmental disorders, CBDA in anxiety and depression, and Δ8-THC in addiction treatment, while revealing that the current studies show only mixed effects for CBG.
SO… While these compounds open exciting doors, the road forward demands more rigorous HUMAN clinical trials and robust regulatory frameworks. Δ8-THC’s safety, CBDA’s stability, and the lack of human studies for CBDV and CBG are just a few hurdles.”